
Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Step by step instructions to Shield Your Wellbeing Around 5G Pinnacles\ - 2
NASA's Perseverance Mars rover could break the record for miles driven on another planet - 3
Taylor Swift just released the 'Elizabeth Taylor' music video — but she's not the star of it - 4
As tetanus vaccination rates decline, doctors worry about rising case numbers - 5
The year's first meteor shower and supermoon clash in January skies
Illumina unveils dataset to speed up AI-powered drug discovery
4 Energy-Proficient Clothes washers to Consider in 2024
Strengthening through Wellness: Individual Preparation Achievement
Home Wellness Basics: Building Your Home Exercise center
AstraZeneca to acquire Modella AI to speed oncology drug research
We may be witnessing the messy death of a star in real time
Ghassan Al-Duhaini to replace Abu Shabab as Popular Forces leader in Gaza
The Best Games Crossroads in History
China Just Got A Lot Closer To Its First-Ever Manned Moon Landing












